Clinical Trials Browser

INDUSTRY × Burkitt Lymphoma × blinatumomab × Clear all

NCT07570173 2026-06-05

MK-1045-005

Phase 2/3 Recruiting

Burkitt Lymphoma

NCT07134088 2026-05-15

A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia

Phase 1/2 Active not recruiting

Burkitt Lymphoma, Recurrence, Neoplasm, Residual

NCT04260022 2025-11-05

Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL

Phase 1 Recruiting

LymphoidMyeloidOther hematologic neoplasm

Blast Crisis, Burkitt Lymphoma, Leukemia, Myeloid, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01207388 2020-02-10

BLAST

Phase 2 Completed

116 enrolled 23 charts 1 FDA

LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Leukemia, Lymphatic Diseases, Lymphoproliferative Disorders, Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01471782 2017-02-08

Clinical Study With Blinatumomab in Pediatric and Adolescent Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia

Phase 1/2 Completed

93 enrolled 21 charts

LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Immunoproliferative Disorders, Leukemia, Leukemia, Lymphoid, Lymphatic Diseases, Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Recurrence, Precursor Cell Lymphoblastic Leukemia-Lymphoma